- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05742386
Impact of Standing Orders Optimization
Evaluating the Impact of Optimizing the Use of HPV Vaccine Standing Orders in Primary Care Clinics
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Katherine Kritikos
- Phone Number: +1 (919) 962-6327
- Email: kkritikos@unc.edu
Study Contact Backup
- Name: Elizabeth Bernstein
- Email: elizabeth_bernstein@unc.edu
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- The University of North Carolina at Chapel Hill
-
Contact:
- Katherine Kritikos
- Phone Number: 919-962-6327
- Email: kkritikos@unc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
This trial will enroll clinics and intervene with clinical staff. We will use vaccination data from children and survey data from clinical staff to evaluate intervention effectiveness. We will not enroll children or interact with them directly.
Inclusion Criteria
Clinics are eligible if they:
- provide HPV vaccine to children ages 9-12
- have standing orders for HPV vaccination approved but not routinely used or be willing to adopt them prior to the start of the trial
- have rates of HPV vaccination (≥1 dose) below 72%, boys and girls combined
Children's medical records will be eligible to be included in the dataset if children:
- are between the ages of 9-12 years at baseline
- are attributed to a participating clinic at 12- or 24-month follow-up
Clinical staff's survey data will be eligible to be included in the dataset if clinical staff complete the follow-up survey.
Exclusion Criteria
Clinics are excluded if they:
- do not provide HPV vaccine to children ages 9-12
- do not have standing orders for HPV vaccination or are not willing to adopt them prior to the start of the trial
- have rates of HPV vaccination (≥1 dose) above 72%, boys and girls combined
- have hosted an AAT workshop in the previous 3 years or are part of current HPV vaccine communication trainings
- have quality improvement efforts to change HPV vaccine standing orders during the trial
Children's medical records will not be eligible to be included in the dataset if children:
- are not between the ages of 9-12 years at baseline
- are not attributed to a participating clinic at 12- or 24-month follow-up
- are receiving hospice/palliative care, are pregnant, or have a history of HPV vaccine contraindications
Clinical staff's survey data will be not eligible to be included in the dataset if clinical staff do not complete the follow-up survey.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HPV vaccine communication training
Staff in clinics randomized to this arm will receive an intervention called Announcement Approach Training (AAT).
This training is designed to improve communication about HPV vaccination.
|
Clinics will host an AAT workshop.
A trained facilitator will use a standard script and slides to deliver workshop in-person or over Zoom; clinical staff who are unavailable will take the workshop later on their own.
|
Experimental: HPV vaccine communication training and standing orders optimization
Staff in clinics randomized to this arm will receive the AAT and conduct a set of activities to optimize use of HPV vaccine standing orders.
|
Clinics will host an AAT workshop, as in the other trial arm. Clinic representatives will attend working meetings on putting HPV vaccine standing orders into clinic workflow. Clinics will then orient their staff to the standing orders. Finally, clinic representatives will discuss their use of standing orders in a learning collaborative. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV vaccination (≥1 dose), 9-12 year olds
Time Frame: from baseline to 12 months
|
Proportion of unvaccinated children who initiate the HPV vaccine series between baseline and 12-month follow-up, among those who were ages 9-12 at baseline.
|
from baseline to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV vaccination (≥1 dose), 9-12 year olds
Time Frame: from 13 months to 24 months
|
Proportion of unvaccinated children who initiate the HPV vaccine series between 13- and 24-month follow-up, among those who were ages 9-12 at 13 months.
|
from 13 months to 24 months
|
HPV vaccination (≥2 doses), 9-12 year olds
Time Frame: from baseline to 12 months
|
Proportion of unvaccinated children who complete the HPV vaccine series between baseline and 12-month follow-up, among those who were ages 9-12 at baseline.
|
from baseline to 12 months
|
HPV vaccination (≥2 doses), 9-12 year olds
Time Frame: from 13 months to 24 months
|
Proportion of unvaccinated children who complete the HPV vaccine series between 13- and 24-month follow-up, among those who were ages 9-12 at 13 months.
|
from 13 months to 24 months
|
Standing orders attitude rating
Time Frame: up to 6 months
|
Positive attitude toward using HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating more positive attitudes.
|
up to 6 months
|
Standing orders norms rating
Time Frame: up to 6 months
|
Norms in favor of using HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating more supportive norms.
|
up to 6 months
|
Standing orders self-efficacy rating
Time Frame: up to 6 months
|
Confidence about using HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating higher confidence.
|
up to 6 months
|
Standing orders adoption rating
Time Frame: up to 6 months
|
Adoption of HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating greater adoption.
|
up to 6 months
|
Standing orders acceptability rating
Time Frame: up to 6 months
|
Acceptability of HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating higher acceptability.
|
up to 6 months
|
Standing orders appropriateness rating
Time Frame: up to 6 months
|
Appropriateness of HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating greater appropriateness.
|
up to 6 months
|
Standing orders role rating
Time Frame: up to 6 months
|
Understanding of role under HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating better understanding of role.
|
up to 6 months
|
Standing orders feasibility rating
Time Frame: up to 6 months
|
Feasibility of HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating greater feasibility.
|
up to 6 months
|
Standing orders sustainability rating
Time Frame: up to 6 months
|
Sustainability of HPV vaccine standing orders will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating greater sustainability.
|
up to 6 months
|
Estimated time spent on recommendations
Time Frame: up to 6 months
|
Time spent on HPV vaccine recommendations will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 0-99 minutes, with higher values indicating more time spent.
|
up to 6 months
|
Estimated recommendation frequency, 9-10 year olds
Time Frame: up to 6 months
|
Frequency of recommending HPV vaccine for children ages 9 or 10 will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating more frequent recommendations.
|
up to 6 months
|
Estimated recommendation frequency, 11-12 year olds
Time Frame: up to 6 months
|
Frequency of recommending HPV vaccine for children ages 11 or 12 will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating more frequent recommendations.
|
up to 6 months
|
Recommendation attitudes rating
Time Frame: up to 6 months
|
Positive attitudes toward recommending HPV vaccine for ages children ages 9 or 10 years will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating more positive recommendation attitudes.
|
up to 6 months
|
Recommendation self-efficacy rating
Time Frame: up to 6 months
|
Confidence in recommending HPV vaccine for children ages 9 or 10 will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating higher recommendation confidence.
|
up to 6 months
|
Recommendation norms rating
Time Frame: up to 6 months
|
Norms in favor of recommending HPV vaccine for children ages 9 or 10 will be measured by one item on the survey, taken by clinical staff two months after attending the AAT.
The range for this measure will be 1 to 5, with higher values indicating more supportive norms.
|
up to 6 months
|
Recommendation intentions rating
Time Frame: up to 6 months
|
Intentions to recommend HPV vaccine for children ages 9 or 10 will be measured by one item on the survey, taken by clinical staff two months after attending the AAT The range for this measure will be 1 to 5, with higher values indicating higher recommendation intentions.
|
up to 6 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Noel T Brewer, PhD, University of North Carolina
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMPACTP1SO
- 5P01CA250989-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Papilloma Virus
-
Regenstrief Institute, Inc.Merck Sharp & Dohme LLCCompletedCervical Cancer | Human Papilloma Virus Infection Type 11 | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Human Papilloma Virus Infection Type 6United States
-
Procare Health Iberia S.L.Adknoma Health ResearchCompletedHuman Papilloma Virus Infection | Human Papilloma Virus | Cervix LesionSpain
-
Emory UniversityNational Institute of Nursing Research (NINR)RecruitingHuman Papilloma Virus | Human Papilloma Virus VaccineUnited States
-
Xiamen Innovax Biotech Co., LtdZhejiang Provincial Center for Disease Control and PreventionActive, not recruitingHuman Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18 | Hepatitis E Virus InfectionChina
-
The Behavioural Insights TeamUNICEF; National Center for Disease Control and Public Health, Georgia; Information...Not yet recruitingHPV, Human Papillomavirus Viruses, Human Papilloma Virus Vaccine
-
Universitair Ziekenhuis BrusselRecruiting
-
Universiti Sains MalaysiaRecruitingHuman Papilloma Virus InfectionMalaysia
-
Universiteit AntwerpenCompletedHuman Papilloma Virus InfectionBelgium
-
Gen-Probe, IncorporatedCompletedHuman Papilloma Virus InfectionUnited States
-
Shanghai Zerun Biotechnology Co.,LtdGuangxi Center for Disease Control and PreventionCompletedCervical Intraepithelial Neoplasia | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18
Clinical Trials on Communication training
-
Montefiore Medical CenterRecruitingCritical Illness | Terminal IllnessUnited States
-
Rutgers, The State University of New JerseyUtah State UniversityCompletedIncreasing Functional Communicative Behavior | Decreasing Destructive Behavior | Analysis of Treatment Dosage | Empirically Determined Reinforcement Schedule ThinningUnited States
-
University Hospital, Basel, SwitzerlandUniversity of Basel; Max Planck Institute for Human DevelopmentCompletedInformation Structuring Skills | Empathy SkillsSwitzerland
-
University of South AlabamaCompletedUsing a Voice Output Communication Aid to Facilitate Language Development in Young Children With ASDAutistic DisorderUnited States
-
Medical University of ViennaCompletedCommunication | Pediatric ALL | End of LifeAustria
-
Johns Hopkins UniversityAgency for Healthcare Research and Quality (AHRQ)Completed
-
Jacobs University Bremen gGmbHGoethe University; University Hospital Ulm; Techniker Krankenkasse; German Coalition... and other collaboratorsCompletedPregnancy RelatedGermany
-
Kari Alyse LeibowitzCompletedHypertension | Diabetes Mellitus | Diabetes | Overweight and Obesity | Pre DiabetesUnited States
-
Jules Bordet InstituteUniversité Catholique de Louvain; Université Libre de Bruxelles; Université de... and other collaboratorsUnknownPhysician Patient RelationshipBelgium
-
University of KentUnknownIntellectual DisabilityUnited Kingdom